ATNM vs. BBOT
ATNM (Actinium Pharmaceuticals, Inc.) and BBOT (BridgeBio Oncology Therapeutics, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Their 0.09 correlation means their historical movements had little consistent relationship.
Performance
ATNM vs. BBOT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ATNM achieves a -38.46% return, which is significantly lower than BBOT's -35.38% return.
ATNM
- 1D
- -0.01%
- 1M
- -14.69%
- 6M
- -27.85%
- YTD
- -38.46%
- 1Y
- -48.02%
- 3Y*
- -51.06%
- 5Y*
- -33.96%
- 10Y*
- -33.78%
- ALL TIME*
- -25.11%
BBOT
- 1D
- -4.82%
- 1M
- -0.25%
- 6M
- -30.97%
- YTD
- -35.38%
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- —
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $68.73K | $77.43K | $122.09K | |
| $2.40M | $3.07M | $3.39M |
ATNM vs. BBOT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | |
|---|---|---|
ATNM Actinium Pharmaceuticals, Inc. | -38.46% | -7.48% |
BBOT BridgeBio Oncology Therapeutics, Inc | -35.38% | 22.75% |
Correlation
The correlation between ATNM and BBOT is 0.09, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (All Time) Calculated using the full available price history since Aug 12, 2025 | 0.09 |
Fundamentals
ATNM:
$26.26M
BBOT:
$648.07M
ATNM:
-$0.75
BBOT:
-$3.43
ATNM:
$90.00K
BBOT:
$0.00
ATNM:
$485.00K
BBOT:
-$194.00K
ATNM:
-$24.68M
BBOT:
-$168.31M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ATNM vs. BBOT — Risk / Return Rank
ATNM
BBOT
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
ATNM vs. BBOT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Actinium Pharmaceuticals, Inc. (ATNM) and BridgeBio Oncology Therapeutics, Inc (BBOT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ATNM | BBOT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | 0.88 | — | — |
| Calmar ratioReturn relative to maximum drawdown | -0.92 | — | — |
| Martin ratioReturn relative to average drawdown | -1.61 | — | — |
Loading charts...
Drawdowns
ATNM vs. BBOT - Drawdown Comparison
The maximum ATNM drawdown since its inception was -99.79%, which is greater than BBOT's maximum drawdown of -48.14%. Use the drawdown chart below to compare losses from any high point for ATNM and BBOT.
Loading charts...
Drawdown Indicators
| ATNM | BBOT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.79% | -48.14% | -51.65% |
Max Drawdown (1Y)Largest decline over 1 year | -53.25% | — | — |
Max Drawdown (3Y)Largest decline over 3 years | -91.54% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -94.19% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -98.61% | — | — |
Current DrawdownCurrent decline from peak | -99.79% | -41.08% | -58.71% |
Average DrawdownAverage peak-to-trough decline | -85.53% | -22.63% | -62.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 30.33% | — | — |
Volatility
ATNM vs. BBOT - Volatility Comparison
Loading charts...
Volatility by Period
| ATNM | BBOT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.91% | — | — |
Volatility (6M)Calculated over the trailing 6-month period | 44.67% | — | — |
Volatility (1Y)Calculated over the trailing 1-year period | 62.04% | 69.10% | -7.06% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 79.98% | 69.10% | +10.88% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 81.51% | 69.10% | +12.41% |
Dividends
ATNM vs. BBOT - Dividend Comparison
Neither ATNM nor BBOT has paid dividends to shareholders.
Financials
ATNM vs. BBOT - Financials Comparison
This section allows you to compare key financial metrics between Actinium Pharmaceuticals, Inc. and BridgeBio Oncology Therapeutics, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ATNM and BBOT have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for ATNM and BBOT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer